TargetMol

10058-F4

Product Code:
 
TAR-T3048
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3048-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-10mg10mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-25mg25mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-50mg50mg£204.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-100mg100mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3048-500mg500mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
10058-F4 is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle arrest and apoptosis.
CAS:
403811-55-2
Formula:
C12H11NOS2
Molecular Weight:
249.35
Pathway:
Autophagy; Cell Cycle/Checkpoint
Purity:
0.9982
SMILES:
CCc1ccc(C=C2SC(S)=NC2=O)cc1
Target:
c-Myc; Autophagy

References

1. Huang MJ, et al. Exp Hematol, 2006, 34(11), 1480-1489. 2. Lin CP, et al. Anticancer Drugs, 2007, 18(2), 161-170. 3. Guo J, et al. Cancer Chemother Pharmacol, 2009, 63(4), 615-625.